Potential Clinical Implications of Senotherapies for Cardiovascular Disease
Circulation Journal · 22.02.2024 · 88 (3) · 277-284
DOI: 10.1253/circj.cj-23-0657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Journal, erschienen am 22.02.2024. Verfasst von Masayoshi Suda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine. Hauptthemen laut MEDLINE: Cellular Senescence, Cardiovascular Diseases. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Aging is a major risk factor for cardiovascular diseases (CVDs) and accumulating evidence indicates that biological aging has a significant effect on the onset and progression of CVDs. In recent years, therapies targeting senescent cells (senotherapies), particularly senolytics that selectively eliminate senescent cells, have been developed and show promise for treating geriatric syndromes and age-associated diseases, including CVDs. In 2 pilot studies published in 2019 the senolytic combination, dasatinib plus quercetin, improved physical function in patients with idiopathic pulmonary fibrosis and eliminated senescent cells from adipose tissue in patients with diabetic kidney disease. More than 30 clinical trials using senolytics are currently underway or planned. In preclinical CVD models, senolytics appear to improve heart failure, ischemic heart disease, valvular heart disease, atherosclerosis, aortic aneurysm, vascular dysfunction, dialysis arteriovenous fistula patency, and pre-eclampsia. Because senotherapies are completely different strategies from existing treatment paradigms, they might alleviate diseases for which there are no current effective treatments or they could be used in addition to current therapies to enhance efficacy. Moreover, senotherapies might delay, prevent, alleviate or treat multiple diseases in the elderly and reduce polypharmacy, because senotherapies target fundamental aging mechanisms. We comprehensively summarize the preclinical evidence about senotherapies for CVDs and discuss future prospects for their clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine.
- Department of Medicine and Physiology and Biomedical Engineering, Mayo Clinic.
- Division of General Internal Medicine, Department of Medicine, Mayo Clinic.
- Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development.
Förderung
- NIA NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Suda, M., Katsuumi, G., Tchkonia, T., Kirkland, J. L., & Minamino, T. (2024). Potential Clinical Implications of Senotherapies for Cardiovascular Disease. Circulation Journal, 88(3), 277-284. https://doi.org/10.1253/circj.cj-23-0657
Vancouver
Suda M, Katsuumi G, Tchkonia T, Kirkland JL, Minamino T. Potential Clinical Implications of Senotherapies for Cardiovascular Disease. Circulation Journal. 2024;88(3):277-284. doi:10.1253/circj.cj-23-0657
BibTeX
@article{Suda2024,
author = {Suda, Masayoshi and Katsuumi, Goro and Tchkonia, Tamar and Kirkland, James L and Minamino, Tohru},
title = {Potential Clinical Implications of Senotherapies for Cardiovascular Disease},
journal = {Circulation Journal},
year = {2024},
volume = {88},
number = {3},
pages = {277--284},
doi = {10.1253/circj.cj-23-0657}
}
EUVIMED